- |||||||||| EDP-297 / Enanta Pharma
EDP-297: a novel, highly potent, farnesoid X receptor agonist, results of a phase 1 study in healthy subjects (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1671;
EDP-297 was generally well tolerated up to 60 μg MAD, with linear PK suitable for once daily oral dosing, target engagement, and no food effect. Overall, EDP-297, a potent and selective FXR agonist,was safe and well tolerated with PK suitable for once daily oral dosing, a strong target engagement and no food effect.
- |||||||||| EDP-297 / Enanta Pharma
EDP-297: A NOVEL, HIGHLY POTENT, FARNESOID X RECEPTOR AGONIST: RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS () - Mar 3, 2022 - Abstract #NASHTAG2022NASH_TAG_92;
Overall, EDP-297, a potent and selective FXR agonist,was safe and well tolerated with PK suitable for once daily oral dosing, a strong target engagement and no food effect. Overall, EDP-297, a potent and selective FXR agonist, was safe and well tolerated with PK suitable for once daily oral dosing, a strong target engagement and no food effect.
- |||||||||| EDP-297 / Enanta Pharma
Trial completion, Trial completion date, Trial primary completion date: A Study of EDP-297 in Healthy Subjects (clinicaltrials.gov) - Oct 29, 2021
P1, N=82, Completed,
Overall, EDP-297, a potent and selective FXR agonist, was safe and well tolerated with PK suitable for once daily oral dosing, a strong target engagement and no food effect. Recruiting --> Completed | Trial completion date: Feb 2021 --> Jun 2021 | Trial primary completion date: Feb 2021 --> Jun 2021
|
